National survey of physicians' perspectives on pharmacogenetic testing in solid organ transplantation

Clin Transplant. 2020 Oct;34(10):e14037. doi: 10.1111/ctr.14037. Epub 2020 Aug 6.


Introduction: Our objective was to evaluate physicians' perspectives on the clinical utility of pharmacogenetic (PGx) testing in kidney, liver, heart, and lung transplantation (KLHL-Tx).

Methods: A 36-question web-based survey was developed and administered to medical and surgical directors of US KLHL-Tx centers.

Results: There were 82 respondents (10% response rate). The majority were men (78%), non-Hispanic whites (70%), medical directors (72%), and kidney transplant physicians (35%). Although 78% of respondents reported having some PGx education, most reported lack of confidence in their PGx knowledge and ability to apply a PGx test. Participants reported mixed views about the clinical utility of PGx testing-most agreed with the efficacy of PGx testing, but not the benefits relative to the risks or standard of care. While 55% reported that testing was available at their institution, only 38% ordered a PGx test in the past year, most commonly thiopurine-S-methyltransferase. Physician-reported barriers to PGx implementation included uncertainty about the clinical value of PGx testing and patient financial burden.

Conclusion: Together, our findings suggest prospective PGx research and pilot implementation programs are needed to elucidate the clinical utility and value of PGx in KLHL-Tx. These initiatives should include educational efforts to inform the use of PGx testing.

Keywords: clinical implementation; personalized medicine; pharmacogenetics; surveys and questionnaires; transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Humans
  • Male
  • Organ Transplantation*
  • Pharmacogenetics
  • Pharmacogenomic Testing
  • Physicians*
  • Prospective Studies